Kidney Disease Impacts Weight Loss After Bariatric Surgery
FRIDAY, Oct. 20, 2023 -- Early-stage chronic kidney disease has a negative impact on short-term weight loss outcomes after bariatric metabolic surgery, according to a study published online Oct. 10 in Obesity Surgery.
Jo ão Pereira, from the School... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 20, 2023 Category: Pharmaceuticals Source Type: news
US FDA Approves Ardelyx's Kidney Disease-Related Drug US FDA Approves Ardelyx's Kidney Disease-Related Drug
The US Food and Drug Administration has approved Ardelyx ' s drug to treat high phosphate levels in patients with chronic kidney disease, the company said, more than 2 years after it was initially rejected.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 18, 2023 Category: Consumer Health News Tags: Nephrology News Source Type: news
FDA Approves First Phosphate Absorption Inhibitor for CKD
(MedPage Today) -- The FDA approved the first-in-class phosphate absorption inhibitor tenapanor (Xphozah) to reduce serum phosphorus in chronic kidney disease (CKD) patients on dialysis, developer Ardelyx announced on Tuesday.
An oral drug, tenapanor... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 18, 2023 Category: American Health Source Type: news
Ardelyx wins long battle for FDA approval of kidney-disease treatment
Ardelyx Inc. ARDX, on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney disease. The biopharma company said late Tuesday that the U.S. Food and Drug Administration approved tenapanor, marketed under the brand name Xphozah, for…#ardelyxincardx #ardelyx #fda #xphozah #mikeraab #atictac (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2023 Category: Consumer Health News Source Type: news
FDA Approves Xphozah (tenapanor) to Reduce Serum Phosphorus in Adults with Chronic Kidney Disease
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 17, 2023 Category: Drugs & Pharmacology Source Type: news
CKD Linked to Cardiac Arrest in Hispanic, Latinx Patients CKD Linked to Cardiac Arrest in Hispanic, Latinx Patients
Chronic kidney disease is associated with a more than sevenfold increase in the risk for sudden cardiac arrest among US residents of Hispanic or Latinx ethnicity, new data suggest.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 16, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
CAC measurements on nongated chest CT improve surgery risk assessment
Estimating the prevalence and severity of coronary artery calcium (CAC) using data gleaned from nongated chest CT imaging improves risk assessment of postsurgical major clinical events before a patient undergoes noncardiac surgery, according to research published in the October 10 issue of Circulation.The study results could improve patients' surgical outcomes, wrote a team led by Daniel Choi, MD, of New York University Grossman School of Medicine in New York City. "[Our study found that] prevalence and severity of coronary calcium from preexisting, preoperative, nongated chest CT imaging were associated with stepwise in...
Source: AuntMinnie.com Headlines - October 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News CT Source Type: news
CKD Strongest Risk Factor for Sudden Cardiac Arrest in Hispanics/Latinos
THURSDAY, Oct. 12, 2023 -- For Hispanic or Latino adults, chronic kidney disease is the strongest risk factor for sudden cardiac arrest (SCA), according to a study published online Oct. 11 in the Journal of the American Heart Association.
Kyndaron... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 12, 2023 Category: Pharmaceuticals Source Type: news
Hispanics With Kidney Disease Face Higher Risk for Cardiac Arrest
THURSDAY, Oct. 12, 2023 -- Hispanic folks with chronic kidney disease should have early heart health screenings, new research suggests, because they ’re at high risk for sudden cardiac arrest.
A team from the Smidt Heart Institute at Cedars-Sinai... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 12, 2023 Category: General Medicine Source Type: news
Redefining CVD Risk: CV-Kidney-Metabolic (CKM) Syndrome Redefining CVD Risk: CV-Kidney-Metabolic (CKM) Syndrome
A new formal definition of CKM syndrome from the American Heart Association reflects the strong interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 10, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
FLOW, a Kidney Outcomes Trial of Semaglutide in T2D and CKD FLOW, a Kidney Outcomes Trial of Semaglutide in T2D and CKD
What have we learned from the FLOW trial about the effects of semaglutide among people with type 2 diabetes and chronic kidney disease?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 6, 2023 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
UAMS Gets $606K to Study Kidney Disease Risk
The study will focus on the relationship between chronic kidney disease, or CKD, and platelets, the small, colorless fragments in blood that form clots and stop or prevent bleeding. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - October 3, 2023 Category: American Health Source Type: news
AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million
The payout will settle the claims of 11,000 people who said they weren ’t property warned Nexium and Prilosec could cause chronic kidney disease. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 3, 2023 Category: Pharmaceuticals Authors: Mary Whitfill Roeloffs, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
Rimidi to Showcase New Chronic Kidney Disease Module at HLTH 2023, Complementing Suite of Chronic Disease Management Solutions
The new module will provide care teams with better visibility into patient data, improving management for patients with Chronic Kidney Disease ATLANTA, Oct. 3, 2023 /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 3, 2023 Category: Pharmaceuticals Tags: PDT Source Type: news
Empagliflozin Gets FDA Nod for CKD Without T2D or HF Empagliflozin Gets FDA Nod for CKD Without T2D or HF
The US Food and Drug Administration gave the SGLT2 inhibitor empagliflozin (Jardiance) a new indication for treating adults with isolated chronic kidney disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 27, 2023 Category: Cardiology Tags: Nephrology News Alert Source Type: news
